Objective: The aim of the study is to compare the efficacy and safety of oral (100 μg) and vaginal (50 μg) misoprostol for labor induction. Study design: Ninety-nine patients with indications for labor induction randomly received 100 μg oral misoprostol every 4 h or 50 μg vaginal misoprostol every 4 h, using maximum six doses. Mean induction to delivery interval, mode of delivery, rates of tachysystole, hypertonus and hyperstimulation syndrome, oxytocin use, number of doses used, failed induction rate and neonatal outcomes were compared for the two groups. Results: Mean dose of misoprostol used for oral and vaginal misoprostol groups were 2.17 ±1.35 and 1.91 ±0.94, respectively (p = 0.65). There were two failed inductions in the oral (4%) and one failed induction (2.5%) in the vaginal group after a total of six doses of misoprostol (p = 0.58). There was no significant difference for the mean induction to delivery interval, to the beginning of active phase interval, active phase dura-tion, second stage duration and the number of women who received oxytocin for induction or augmentation between the two groups (p >0.05). There were also no significant differences for intrapartum complications and neonatal outcomes between the oral and vaginal misoprostol groups (p >0.05). Conclusion: Our findings indicate that, in a closely supervised hospital setting with adequate monitoring, 100 μg oral misoprostol has the potential to induce labor as safely and effectively as its 50 μg vaginal analogue. As oral use of the drug is easier for both the patient and the doctor, oral misoprostol will probably be more preferable than the vaginal route. Objective: The aim of the study is to compare the efficacy and safety of oral (100 μg) and vaginal (50 μg) misoprostol for labor induction. Study design: Ninety-nine patients with indications for labor induction randomly received 100 μg oral misoprostol every Mean induction to delivery interval, mode of delivery, rates of tachysystole, hypertonus and hyperstimulation syndrome, oxytocin use, number of doses used, failed induction rate and neonatal outcomes were 4 h or 50 μg vaginal misoprostol every 4 h, using maximum six doses. compared for the two groups. Results: Mean dose of misoprostol used for oral and vaginal misoprostol groups were 2.17 ± 1.35 and 1.91 ± 0.94, respectively (p = 0.65). There were two failed inductions in the oral (4%) and one failed induction (2.5%) in the vaginal group after a total of six doses of misoprostol (p = 0.58). There was no significant difference for the mean induction to delivery interval, to the beginning of active phase interval, active phase d ura-tion, second stage duration and the number of women who received oxytocin for induction or augmentation between the two groups (p> 0.05). There were also no significant differences for intrapartum complications and neonatal outcomes between the oral and vaginal misoprostol groups (p > 0.05). Conclusion: Our findings indicate that, in a closely supervised hospital setting with adequate monitoring, 100 μg oral misoprostol has the potential to induce labor as safely and effectively as its 50 μg vaginal analogue. for both the patient and the doctor, oral misoprostol will probably be more preferable than the vaginal route.